Personal information

Activities

Collapse all

Works (5)

Hybrid Email and Outpatient Clinics to Optimize Maintenance Therapy in Acute Lymphoblastic Leukemia

Journal of Pediatric Hematology/Oncology
2024-01 | Journal article
DOI: 10.1097/MPH.0000000000002796
Contributors: Tushar Mungle; Ananya Mahadevan; Parag Das; Amit K. Mehta; Manash P. Gogoi; Bishwaranjan Jana; Niharendu Ghara; Debjani Ghosh; Vaskar Saha; Shekhar Krishnan
Source: check_circle
Crossref

Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer

Indian Journal of Pediatrics
2024-01 | Journal article
DOI: 10.1007/s12098-023-04687-6
Contributors: Shekhar Krishnan; Ananya Mahadevan; Tushar Mungle; Manash Pratim Gogoi; Vaskar Saha
Source: check_circle
Crossref

Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017–2019

Cancer Medicine
2023-04 | Journal article
DOI: 10.1002/cam4.5677
Contributors: Anindita Dutta; Tushar Mungle; Nandita Chowdhury; Pritha Banerjee; Anisha Gehani; Saugata Sen; Mohandas Mallath; Paromita Roy; Shekhar Krishnan; Sandip Ganguly et al.
Source: check_circle
Crossref

High treatment related mortality due to infection remains a major challenge in the management of high-grade B-cell Non-Hodgkin Lymphoma in children in developing countries: Experience from a tertiary cancer center in Eastern India

Pediatric Hematology Oncology Journal
2022-06 | Journal article
DOI: 10.1016/j.phoj.2022.03.180
Contributors: Avijeet Kumar Mishra; Shekhar Krishnan; Arpita Bhattacharyya; K.S. Reghu; Anirban Das; Sheetal Kulkarni Modi; Parag Das; Niharendu Ghara
Source: check_circle
Crossref

Reply to: Comment on: Unsatisfactory quality of E. coli asparaginase biogenerics in India—Implications for clinical outcomes in acute lymphoblastic leukaemia

Pediatric Blood & Cancer
2022-02 | Journal article
DOI: 10.1002/pbc.29334
Contributors: Jasmeet Sidhu; Vaskar Saha; Shekhar Krishnan
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for Cancer chemotherapy and pharmacology. (1)
How many people are using ORCID?